799 related articles for article (PubMed ID: 28148701)
1. Need for Improvement in Current Treatment of Psoriatic Arthritis: Study of an Outpatient Clinic Population.
Michelsen B; Diamantopoulos AP; Høiberg HK; Soldal DM; Kavanaugh A; Haugeberg G
J Rheumatol; 2017 Apr; 44(4):431-436. PubMed ID: 28148701
[TBL] [Abstract][Full Text] [Related]
2. Ultrasonographic evaluation in psoriatic arthritis is of major importance in evaluating disease activity.
Michelsen B; Diamantopoulos AP; Hammer HB; Soldal DM; Kavanaugh A; Haugeberg G
Ann Rheum Dis; 2016 Dec; 75(12):2108-2113. PubMed ID: 27091837
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort.
Lubrano E; De Socio A; Perrotta FM
J Rheumatol; 2017 Aug; 44(8):1159-1164. PubMed ID: 28572467
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Response to Treatment, Remission, and Minimal Disease Activity in Axial Psoriatic Arthritis Treated with Tumor Necrosis Factor Inhibitors.
Lubrano E; Parsons WJ; Perrotta FM
J Rheumatol; 2016 May; 43(5):918-23. PubMed ID: 26980581
[TBL] [Abstract][Full Text] [Related]
5. Disparity between ultrasound and clinical findings in psoriatic arthritis.
Husic R; Gretler J; Felber A; Graninger WB; Duftner C; Hermann J; Dejaco C
Ann Rheum Dis; 2014 Aug; 73(8):1529-36. PubMed ID: 23740228
[TBL] [Abstract][Full Text] [Related]
6. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.
Perrotta FM; Marchesoni A; Lubrano E
J Rheumatol; 2016 Feb; 43(2):350-5. PubMed ID: 26669925
[TBL] [Abstract][Full Text] [Related]
7. Disease activity in psoriatic arthritis: comparison of the discriminative capacity and construct validity of six composite indices in a real world.
Salaffi F; Ciapetti A; Carotti M; Gasparini S; Gutierrez M
Biomed Res Int; 2014; 2014():528105. PubMed ID: 24967375
[TBL] [Abstract][Full Text] [Related]
8. Residual symptoms and disease burden among patients with psoriatic arthritis: is a new disease activity index required?
Kilic G; Kilic E; Nas K; Kamanlı A; Tekeoglu İ
Rheumatol Int; 2019 Jan; 39(1):73-81. PubMed ID: 30426235
[TBL] [Abstract][Full Text] [Related]
9. Gender does not make a difference in "composite psoriatic disease activity index (CPDAI)" in patients with psoriatic arthritis.
Kenar G; Yarkan H; Zengin B; Can G; Birlik M; Önen F
Rheumatol Int; 2018 Nov; 38(11):2069-2076. PubMed ID: 30194455
[TBL] [Abstract][Full Text] [Related]
10. Remission criteria and activity indices in psoriatic arthritis.
Acosta Felquer ML; Ferreyra Garrott L; Marin J; Catay E; Scolnik M; Scaglioni V; Ruta S; Rosa J; Soriano ER
Clin Rheumatol; 2014 Sep; 33(9):1323-30. PubMed ID: 24820142
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Composite Measure Remission Targets in Psoriatic Arthritis.
Farkas F; Ikumi N; Elmamoun M; Szentpetery A; FitzGerald O
J Rheumatol; 2021 Aug; 48(8):1272-1278. PubMed ID: 33722944
[TBL] [Abstract][Full Text] [Related]
12. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA).
Theander E; Husmark T; Alenius GM; Larsson PT; Teleman A; Geijer M; Lindqvist UR
Ann Rheum Dis; 2014 Feb; 73(2):407-13. PubMed ID: 23355078
[TBL] [Abstract][Full Text] [Related]
13. Comparison of disease activity measures in early psoriatic arthritis in usual care.
Wervers K; Luime JJ; Tchetverikov I; Gerards AH; Kok MR; Appels CWY; van der Graaff WL; van Groenendael JHLM; Korswagen LA; Veris-van Dieren JJ; Hazes JMW; Vis M;
Rheumatology (Oxford); 2019 Dec; 58(12):2251-2259. PubMed ID: 31211399
[TBL] [Abstract][Full Text] [Related]
14. Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease.
Helliwell P; Coates LC; FitzGerald O; Nash P; Soriano ER; Elaine Husni M; Hsu MA; Kanik KS; Hendrikx T; Wu J; Kudlacz E
Arthritis Res Ther; 2018 Oct; 20(1):242. PubMed ID: 30373651
[TBL] [Abstract][Full Text] [Related]
15. Impact of skin, musculoskeletal and psychosocial aspects on quality of life in psoriatic arthritis patients: A cross-sectional study of outpatient clinic patients in the biologic treatment era.
Haugeberg G; Michelsen B; Kavanaugh A
RMD Open; 2020 May; 6(1):. PubMed ID: 32409518
[TBL] [Abstract][Full Text] [Related]
16. A 2-year observational study on treatment targets in psoriatic arthritis patients treated with TNF inhibitors.
Chimenti MS; Triggianese P; Conigliaro P; Tonelli M; Gigliucci G; Novelli L; Teoli M; Perricone R
Clin Rheumatol; 2017 Oct; 36(10):2253-2260. PubMed ID: 28762060
[TBL] [Abstract][Full Text] [Related]
17. Psoriatic arthritis: improvement in outcomes but persistent sex difference - 5-year follow-up study of a Norwegian outpatient clinic population.
Łosińska K; Michelsen B; Kavanaugh A; Korkosz M; Haugeberg G
Scand J Rheumatol; 2024 Jan; 53(1):10-20. PubMed ID: 37656147
[TBL] [Abstract][Full Text] [Related]
18. Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial.
Helliwell PS; Deodhar A; Gottlieb AB; Boehncke WH; Xu XL; Xu S; Wang Y; Hsia EC; Gladman DD; Ritchlin CT
Arthritis Care Res (Hoboken); 2020 Nov; 72(11):1579-1588. PubMed ID: 31421033
[TBL] [Abstract][Full Text] [Related]
19. Ten years of follow-up data in psoriatic arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway.
Haugeberg G; Michelsen B; Tengesdal S; Hansen IJW; Diamantopoulos A; Kavanaugh A
Arthritis Res Ther; 2018 Aug; 20(1):160. PubMed ID: 30071892
[TBL] [Abstract][Full Text] [Related]
20. Residual Disease Activity and Associated Factors in Psoriatic Arthritis.
Lubrano E; Scriffignano S; Perrotta FM
J Rheumatol; 2020 Oct; 47(10):1490-1495. PubMed ID: 31676704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
